Robert Aran, DO
Gastroenterology · Tulsa, OKNPI 1003357039
Payments from drug & device makers
Across 254 payments — averaging $25.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Boston Scientific$1K
- Gilead$385
- Pfizer$355
- Intercept Pharmaceuticals, Inc.$319
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$309
- plus $2K from 23 others
What the payments were for
- Travel & lodging$5969%
- Food & beverage$5,98991%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 114 | $2,476 |
| Boston Scientific | 12 | $1,162 |
| Gilead | 14 | $385 |
| Pfizer | 19 | $355 |
| Intercept Pharmaceuticals, Inc. | 18 | $319 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $309 |
| E.r. Squibb & Sons, L.L.C. | 3 | $242 |
| Johnson & Johnson | 8 | $156 |
| Viiv Healthcare Company | 4 | $153 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $134 |
| Merck | 2 | $132 |
| Madrigal Pharmaceuticals | 6 | $113 |
| Janssen Scientific Affairs, LLC | 1 | $108 |
| Regeneron Healthcare Solutions, Inc. | 4 | $103 |
| Phathom Pharmaceuticals, Inc. | 7 | $76 |
| Lilly USA, LLC | 3 | $67 |
| Ipsen Biopharmaceuticals, Inc | 3 | $56 |
| Sanofi | 3 | $54 |
| Bristol Myers Squibb | 2 | $29 |
| QOL Medical, LLC | 1 | $27 |
| Shionogi Inc | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Sandoz | 1 | $18 |
| Ardelyx, Inc. | 1 | $17 |
| Celltrion USA Inc. | 1 | $16 |
| Braintree Laboratories, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Ambu Inc. | 1 | $14 |
| Micro-tech Endoscopy USA, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,602 in reported general payments places this provider in the 50th percentile of 133 gastroenterology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcalivaObeticholic Acid | 15 | $163,462 |
| XifaxanRifaximin | 22 | $63,079 |
| LinzessLinaclotide | 53 | $41,573 |
| CreonLipase/Protease/Amylase | 31 | $39,401 |
| TrulancePlecanatide | 22 | $15,658 |
| Mesalamine | 14 | $6,122 |
| MovantikNaloxegol Oxalate | 13 | $5,055 |
| Pantoprazole Sodium | 171 | $2,728 |
| Ursodiol | 22 | $2,378 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 117 | $1,744 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 86 | $1,258 |
| Esomeprazole Magnesium | 27 | $1,229 |
| Omeprazole | 73 | $1,113 |
| CholestyramineCholestyramine (With Sugar) | 16 | $986 |
| Lansoprazole | 13 | $648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Intercept Pharmaceuticals, Inc.Ocaliva | $319 | $163,46215 claims |
| AbbVieLinzess, Creon | $2,476 | $80,97484 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $309 | $78,73744 claims |
| SandozLansoprazole | $18 | $64813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 133 gastroenterology providers in Oklahoma.
Other gastroenterology in Tulsa
- Harvey TatumTulsa$2.6M
- Aaron FiekerTulsa$232K
- Kevin McNamaraTulsa$223K
- David MorrisTulsa$211K
- Jeffrey HuntTulsa$155K
- Roy ThompsonTulsa$16K
- Vasudevan RaghuramanTulsa$14K
- William BriggsTulsa$14K
- Sheldon BergerTulsa$14K
- Patrick VolakTulsa$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.